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Abstract The preliminary cytotoxic effect of 4-
ethoxycarbonylmethyl-1-(piperidin-4-ylcarbonyl)-thiosemi-
carbazide hydrochloride (1)—a potent topoisomerase II in-
hibitor—was measured using a MTT assay. It was found that
the compound decreased the number of viable cells in both
estrogen receptor-positive MCF-7 and estrogen receptor-
negative MDA-MB-231breast cancer cells, with IC50 values
of 146±2 and 132±2 μM, respectively. To clarify the molec-
ular basis of the inhibitory action of 1, molecular docking
studies were carried out. The results suggest that 1 targets the
ATP binding pocket.
Keywords Thiosemicarbazide derivative . Human
topoisomerase II . Cytotoxicity . Molecular docking .
DFTcalculation
Introduction
An important chemotherapeutic target in the treatment of
cancer is the ATP-dependent enzyme topoisomerase II
(Topo II), which regulates the conformational changes in
DNA topology necessary for transcription, replication, and
chromosome condensation and segregation [1, 2]. Currently,
six Topo II inhibitors (etoposide, teniposide, doxorubicin,
daunorubicin, idarubicin, and mitoxantrone) are prescribed
as highly anti-neoplastic drugs in clinical use. However,
emerging tumor resistance and several side effects, such as
hematological toxicity, nausea and vomiting, and hair loss,
are associated with them [3, 4]. Therefore, efforts have been
made by many research groups to find new chemicals with
improved bioactivity. Although many compounds were
found as cytostatic agents and Topo II and(or) I inhibitors,
most showed significant toxicity for normal dividing cells,
which precludes their use as drugs or lead molecule candi-
dates [5]. The discovery of new types of Topo II inhibitors
that can be synthesized easily, show increased sensitivity in
drug resistant tumors and decreased dose-limiting toxicities
would be a significant addition to the choices available in
the treatment of cancer.
Recently, as part of a search for the molecular basis of
antibacterial activity of thiosemicarbazide-based com-
pounds, we documented for the first time that one of the
mechanisms of the bioactivity of these molecules is
connected with inhibition of bacterial Topo IV [6–8]. Since
both bacterial and human topoisomerases share a unique
structural ATP-binding motif, called the Bergerat fold [9],
we decided to conduct enzymatic studies to determine
the effect of thiosemicarbazide derivatives on human top-
oisomerases. We found that the title compound, 4-
ethoxycarbonylmethyl-1-(piperidin-4-ylcarbonyl)-thiosemi-
carbazide hydrochloride (1) selectively inhibited Topo II
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activity almost completely at 15 μM concentration, proving
more potent than etoposide under the same experimental
conditions [10]. To expand our initial findings with further
details on the biological action pathways of 1, the com-
pound was further assessed by preliminary cytotoxicity
measurements. Herein we present the results of these inves-
tigations, as well as those of subsequent docking studies and
DFTcalculations, which allowed us to suggest that compound
1 targets the ATP binding pocket.
Materials and methods
Etoposide and camptothecin were purchased from TopoGEN
(http://www.topogen.com/). Stock cultures of breast cancer
MCF-7 and MDA-MB-231 were purchased from the Ameri-
can Type Culture Collection (Rockville, MD). Dulbecco’s
minimal essential medium (DMEM) and foetal bovine serum
(FBS) used in cell culture were products of Gibco (http://
www.invitrogen.com/site/us/en/home/brands/Gibco.html).
Glutamine, penicillin and streptomycin were obtained from
Quality Biologicals (Gaithersburg, MD). [3H]-Thymidine
(6.7 Ci/mmol) was the product of NEN (Boston, MA).
Cell culture
Human breast cancer MDA-MB-231 and MCF-7 cells
maintained in DMEM supplemented with 10 % fetal bovine
serum (FBS), 50 U/ml penicillin, 50 μg/ml streptomycin at
37 °C. Cells were cultured in Costar flasks and subconfluent
cells were detached with 0.05 % trypsin and 0.02 % EDTA
in calcium-free phosphate buffered saline, counted in hemo-
cytometers and plated at 5×105 cells per well in six-well
plates (Nunc, http://www.nuncbrand.com) in 2 ml of growth
medium (DMEM without phenol red with 10 % CPSR1).
Cells reached about 80 % of confluency at day 3 and in most
cases such cells were used for the assays.
Cytotoxic assay
To examine the effect of the studied drugs on MCF-7 and
MDA-MB-231cell proliferation, the cells were seeded in 24-
well tissue culture dishes at 1×105 cells/well with 1 ml growth
medium. After 48 h (1.8±0.1×105 cells/well) plates were
incubated with varying concentrations of compound 1, chlor-
ambucil and 0.5 μCi [3H]-thymidine for 24 h at 37 °C. Cells
were rinsed three times with PBS, solubilised with 1 ml 0.1 M
sodium hydroxide containing 1 % SDS, scintillation fluid
(9 ml) was added and radioactivity incorporation into DNA
was measured in a scintillation counter.
Cell viability assay
The assay was performed according to the method of
Carmichael [11] using 3-(4,5-dimethylthiazole-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (Sigma, St. Louis,
MO). Confluent cells, cultured for 24 h with various con-
centrations of the studied compounds in six-well plates were
washed three times with PBS and then incubated for 4 h in
1 ml MTT solution (5 mg/ml PBS) at 37 °C in 5 % CO2 in
an incubator. The medium was removed and 1 ml 0.1 M
HCl in absolute isopropanol was added to attached cells.
Absorbance of converted dye in living cells was measured at
a wavelength of 570 nm. Cell viability of breast cancer cells
cultured in the presence of ligands was calculated as a per








Fig. 2 Viability of MCF-7 (a)
and MDA-MB-231 (b) cells
treated for 24 h with different
concentrations of compound 1
and chlorambucil. Mean
values ± SD from three inde-
pendent experiments performed
in duplicate are presented
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Automated docking setup
Docking was performed by means of the FlexX program
[12] as implemented in LeadIT software package [13] using
models of Topo II binding site complexed with AMP-PNP
(PDB id 1ZXN [14]) and etoposide (PDB id 3QX3 [15]) as
templates. The ligand within the active site and all water
molecules were removed while magnesium ion was allowed
to remain with the charge of +2. The active site was defined
to include all atoms within 6.5 Å radius of the native ligand.
The first 100 top ranked docking poses were saved for each
docking run. Subsequently, compounds 1–3 were docked
using same docking parameters. Both rigid and flexible
docking was performed (the results for the latter are pre-
sented). For compounds 1 and 3, both piperidine protonated
and deprotonated forms were considered.
DFT calculations
Following the methodology used previously [16] energies of
best poses of compounds 1–4 obtained from FlexX docking
were calculated using the B3LYP functional [17, 18]
expressed in the basis set of 6–31 G(d) [19–21] as imple-
mented in Gaussian 09 [22] to describe their molecular prop-
erties. Natural population analysis (NPA) phase of NBO was
used [23]. The highest occupied (HOMO) and lowest unoc-
cupied (LUMO) molecular orbitals were illustrated using the
GaussView 5.0 program [24].
Statistical analysis
In all experiments, the mean values for six independent experi-
ments ± standard deviations (SD) were calculated, unless other-
wise indicated. The results were submitted to statistical analysis
using Students t-test, accepting P<0.05 as significant.
Results and discussion
The titled 4-ethoxycarbonylmethyl-1-(piperidin-4-ylcarbonyl)-
thiosemicarbazide hydrochloride, 1, was synthesized through
the route outlined in Fig. 1; details of the synthetic procedure,
structural characterization of 1 and its effect on human topoiso-
merase II activity are described in our patent application [10].
Cytotoxic effect of 1
Many reports in recent years have indicated that inhibitory action
towards Topo II coincides with cytotoxic properties for several
naturally occurring and synthetic compounds [25–30]. We there-
fore subjected 1 to a preliminaryMTTassay in estrogen receptor-
positive (MCF-7) and estrogen receptor-negative (MDA-MB-
231) breast cancer cells to identify any possible correlation.
Compound 1 decreased the number of viable cells in both
MCF-7 and MDA-MB-231 breast cancer cells; however, at
somewhat higher concentrations than the positive control chlor-
ambucil. The inhibitory activities (IC50) of compound 1 on
Fig. 3 Cytotoxic effects of
compound 1 and chlorambucil
on the cultured breast cancer
cell lines MDA-MB-231 (a)
and MCF-7 (b) as measured by
inhibition of [3H]-thymidine in-
corporation into DNA. Mean
values ± SD of three independent
experiments performed in dupli-
cate are presented
Fig. 4 Interactions between 1
and the residues of the
DNA-(left) and ATP-(right)
binding sites
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MDA-MB-231 and MCF-7 were 146±2 and 132±2 μM, re-
spectively, whereas that of chlorambucil were 92±2 and 97±
2μM, respectively, as shown in Fig. 2. Although the cytotoxicity
of 1 was concentration-dependent in both cell lines, it was more
pronounced at shorter times in MDA-MB-231 than in MCF-7.
The above data was corroborated by a cell proliferation
assay. The profiles of DNA synthesis were found to be similar
in MCF-7 andMDA-MB-231 (Fig. 3). The concentration of 1
required to inhibit [3H]-thymidine incorporation into DNA by
50 % (IC50) in MDA-MB-231 was found to be 123±2 μM,
suggesting a lower cytotoxic potency compared to chloram-
bucil (IC50056±2 μM). The concentrations of 1 and chlor-
ambucil required for 50 % inhibition of [3H]-thymidine
incorporation into DNA in breast cancer MCF-7 cells (IC50)
were 124±2 μM and 65±2 μM, respectively.
Computational studies
To examine the mode of inhibitory action of 4-
ethoxycarbonylmethyl-1-(piperidin-4-ylcarbonyl)-thiosemicar-
bazide hydrochloride, 1, docking simulations were performed
withATP-binding domain of hTopoIIα (PDB: 1ZXM) andDNA
binding site of hTopoIIβ (PDB id: 3QX3) using the FlexX
program, which has been shown to be reliable enough to carry
out binding mode analysis of ligands in ATP binding pocket of
hTopoIIα [31]. To validate the molecular docking protocol,
AMPPNP and etoposide (bound ligands) were initially docked
into the crystal structure of the enzyme. The docked ligands were
found to have similar binding poses to the co-crystallized ligand,
thus validating the adopted docking methodology. We then
docked 1 into the DNA and ATP binding sites, respectively,
and its interactions with the target enzyme were analyzed. In
both cases, crystallographic water molecules were treated rotat-
able and displaceable. Their contribution to binding was found
negligible in all cases. Free energies of binding of 1, obtained
from the Hyde scoring function [32, 33], are 9 kJ/mol in the
DNAactive site while it is−20 kJ/mol in theATP binding site (vs
−6 kJ/mol for AMPPNP, 2, an analog of ATP crystallized with
hTopoIIα). From this data we conclude that 1 has greater affinity
toward the ATP binding site than to the DNA binding pocket of
hTopoIIα and is an even more effective inhibitor than AMPPNP.
Figures 4 and 5 show interactions of 1 in DNA and ATP active
sites. As can be seen, compound 1 fits well into the ATP pocket,
forming 11 hydrogen bonding interactions with water molecules,
Gly164, Asn163, Arg162, Glu87, Gly166, Tyr165 and hydro-
phobic interactions with Gly160, Gly161, Asn91.
To test the docking predictions, we repeated the docking
simulationswith the closely related structural analog of 1, 4-(4-
methoxyphenyl)-1-(piperidin-4-ylcarbonyl)-thiosemicarba-
zide hydrochloride 3 (Fig. 6), which was found to be inactive
in our enzyme bioassays. Consistent with these results, the
docking calculations correctly predict lack of stability of the
active site—compound 3 complex (27 kJ/mol), confirming the
reliability of the employed docking methodology.
Most recently, some meaningful results concerning the
ligand recognition process in the ATP binging site were de-
scribed by Ma and co-workers [16]. In this latter communica-
tion, the authors applied a combination of molecular docking
approaches, DFT calculations, and CoMFA/CoMSIA meth-
ods to explore the possible binding modes of hTopo II inhib-
itors with the naphthoquinone core structure. Based on the
best-scored conformations obtained from the FlexX docking
simulation they generated the distribution of frontier molecu-
lar orbitals and found significant differences between potent
and weak inhibitors in their HOMO distribution. The HOMO
of the potent inhibitors covered almost the whole molecule
while weak inhibitors had their HOMO outside the phenyl
ring. It was thus proposed that distribution of HOMO
Fig. 5 Docking results with
ATP-binding domain of
hTopoIIα (PDB: 1zxm). Left
Superposition of the native ligand
AMPPNP (rendered as tubes),
and the best conformation of 1.
Right Binding mode of 1
HCl





was found to be inactive
as hTopo II inhibitor
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significantly affects the binding of ligands to the ATP pocket.
Following these findings, and using the same level of theory,
we generated the HOMO orbitals for 1 and 3 and compared
them with HOMO of the potent hTopoIIα catalytic inhibitor
(which we refer to as 4, Fig. 7) from the closely related class
reported earlier in the literature [34]. Comparison of the orbi-
tals leads to the conclusion that there is no similarity between
HOMO distributions of the studied compounds and
AMPPNP. A similar conclusion can be drawn from analysis
of the LUMO distributions (MOs are given in Fig. S1 in the
Supplementary Material). Thus it seems that the electronic
distribution in the frontier orbitals is not related to inhibitory
activity of studied compounds against Topo II—a conclusion
in line with the lack of covalent bonding between inhibitor and
active site residues.
Conclusions
In this contribution we show compound 1 to be highly selective
and potent inhibitor of human Topo II. From docking simula-
tions, we conclude that its inhibitory action is connected with
the ATP binding pocket although competitive inhibition assays
are needed to confirm this hypothesis. These results will aid the
rational design of novel thiosemicarbazide-based compounds
that target the inhibition of Topo II and will provide insights
into the discovery of novel anticancer agents.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
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